Atopalm Acne Controlling
NDC 51141-7000
Product Information
Atopalm Acne Controlling is a OTC MONOGRAPH FINAL-approved product labeled by Neopharm Co., Ltd.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 51141-7000 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 51141-7000?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SALICYLIC ACID (UNII: O414PZ4LPZ)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
- BUTYLENE GLYCOL (UNII: 3XUS85K0RA)
- CETYL ALCOHOL (UNII: 936JST6JCN)
- DIMETHICONE (UNII: 92RU3N3Y1O)
- GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
- OCTYLDODECANOL (UNII: 461N1O614Y)
- POLYSORBATE 60 (UNII: CAL22UVI4M)
- ARGININE (UNII: 94ZLA3W45F)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- MYRISTOYL/PALMITOYL OXOSTEARAMIDE/ARACHAMIDE MEA (UNII: 1211AIM8G7)
- ALLANTOIN (UNII: 344S277G0Z)
- CHOLESTEROL (UNII: 97C5T2UQ7J)
- XANTHAN GUM (UNII: TTV12P4NEE)
- POLYQUATERNIUM-7 (70/30 ACRYLAMIDE/DADMAC; 1600 KD) (UNII: 0L414VCS5Y)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- C13-14 ISOPARAFFIN (UNII: E4F12ROE70)
- LAURETH-7 (UNII: Z95S6G8201)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 103568 - salicylic acid 2 % Topical Lotion
- RxCUI: 103568 - salicylic acid 20 MG/ML Topical Lotion
* Please review the full disclaimer at the bottom of this page.